Thursday, November 26, 2009

Clavis Pharma, Clovis Oncology ink pact to develop & commercialise pancreatic cancer drug CP-4126

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc, the newly formed oncology company led by former Pharmion Corporation executives, announced an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in phase-II development in pancreatic cancer.

The details can be read here.

No comments: